These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 6141576)

  • 1. The prediction of acute response, remission and general outcome of neuroleptic treatment in acute schizophrenic patients.
    Nedopil N; Pflieger R; Rüther E
    Pharmacopsychiatria; 1983 Nov; 16(6):201-5. PubMed ID: 6141576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prediction of therapeutic success in acute neuroleptic treatment: results of an empirical study of 243 inpatient-treated schizophrenic patients].
    Möller HJ; Scharl W; von Zerssen D
    Fortschr Neurol Psychiatr; 1985 Oct; 53(10):370-83. PubMed ID: 2866152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial improvement as predictor of outcome of neuroleptic treatment.
    Nedopil N; Rüther E
    Pharmacopsychiatria; 1981 Nov; 14(6):205-7. PubMed ID: 6119712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suspension of neuroleptic therapy in acute schizophrenia.
    Kuhs H; Eikelmann B
    Pharmacopsychiatry; 1988 Jul; 21(4):197-202. PubMed ID: 2905064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of "natural" course, relapse and prophylactic response in schizophrenic patients.
    Pietzcker A; Gaebel W
    Pharmacopsychiatria; 1983 Nov; 16(6):206-11. PubMed ID: 6141577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autonomic nervous system differences as predictors of short-term outcome in schizophrenics.
    Straube ER; Schied HW; Rein W; Breyer-Pfaff U
    Pharmacopsychiatry; 1987 May; 20(3):105-10. PubMed ID: 2885864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of the emotional blunting and its prognostic importance during neuroleptic treatment of schizophrenia].
    Kukulska D
    Psychiatr Pol; 2003; 37(6):999-1012. PubMed ID: 14727372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics.
    Szymanski S; Lieberman J; Pollack S; Kane JM; Safferman A; Munne R; Umbricht D; Woerner M; Masiar S; Kronig M
    Biol Psychiatry; 1996 Feb; 39(4):249-54. PubMed ID: 8645771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible predictors of neuroleptic-resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effects.
    Kinon BJ; Kane JM; Chakos M; Munne R
    Psychopharmacol Bull; 1993; 29(3):365-9. PubMed ID: 7907184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electroencephalography in schizophrenic patients: comparison between neuroleptic-naive state and after treatment.
    Nagase Y; Okubo Y; Toru M
    Biol Psychiatry; 1996 Sep; 40(6):452-6. PubMed ID: 8879464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antidepressive effect of pyridoxine (vitamin B6) in neuroleptic-treated schizophrenic patients with co-morbid minor depression--preliminary open-label trial].
    Shiloh R; Weizman A; Weizer N; Dorfman-Etrog P; Munitz H
    Harefuah; 2001 May; 140(5):369-73, 456. PubMed ID: 11419053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone.
    Kopala LC; Fredrikson D; Good KP; Honer WG
    Biol Psychiatry; 1996 Feb; 39(4):296-8. PubMed ID: 8645777
    [No Abstract]   [Full Text] [Related]  

  • 13. Predictive validity of proposed remission criteria in first-episode schizophrenic patients responding to antipsychotics.
    Wunderink L; Nienhuis FJ; Sytema S; Wiersma D
    Schizophr Bull; 2007 May; 33(3):792-6. PubMed ID: 16894026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haloperidol plasma level after a test dose as predictor for the clinical response to treatment in acute schizophrenic patients.
    Louza Neto MR; Müller-Spahn F; Rüther E; Scherer J
    Pharmacopsychiatry; 1988 Sep; 21(5):226-31. PubMed ID: 3227054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction and evaluation criteria in perazine therapy of acute schizophrenics. Methodological considerations, sample population, and research variables.
    Rein W; Schied HW; Breyer-Pfaff U; Straube E
    Pharmacopsychiatria; 1983 Sep; 16(5):147-51. PubMed ID: 6140693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Discontinuation of antipsychotic drugs in chronic schizophrenic patients. II. Psychological and psychopathological test differences between patients with and without relapse].
    Woggon B; Bickel P; Schnyder B
    Int Pharmacopsychiatry; 1979; 14(5):278-93. PubMed ID: 43849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
    Harvey PD; Davidson M; White L; Keefe RS; Hirschowitz J; Mohs RC; Davis KL
    Biol Psychiatry; 1996 Oct; 40(8):755-60. PubMed ID: 8894068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developmental and neurologic correlates of treatment response in schizophrenia.
    Whelton CL; Cleghorn JM; Atley S; Durocher GJ; MacCrimmon D
    J Psychiatry Neurosci; 1992 Mar; 17(1):15-22. PubMed ID: 1349824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subjective response and attitudes toward antipsychotic drug therapy during the initial treatment period: a prospective follow-up study in patients with schizophrenia.
    Hofer A; Rettenbacher MA; Edlinger M; Kemmler G; Widschwendter CG; Fleischhacker WW
    Acta Psychiatr Scand; 2007 Nov; 116(5):354-61. PubMed ID: 17868428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of neuroleptic treatment response in acute schizophrenia: results of a treatment study with perazine.
    Gaebel W; Pietzcker A; Ulrich G; Schley J; Müller-Oerlinghausen B
    Pharmacopsychiatry; 1988 Nov; 21(6):384-6. PubMed ID: 2907645
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.